Form 8-K · Current report
Amcor 8-K, filed Aug 12, 2026
- Filed
- CIK
- 0001748790
- Accession no.
- 0001748790-26-000020
Summary
Amcor reported fiscal 2026 fourth-quarter net sales of $6.4 billion, up 26%, and net income of $389 million, with full-year net sales of $23.5 billion, up 57% largely from the Berry Global acquisition, and declared a quarterly dividend of 65.0 cents per share. CEO Peter Konieczny credited synergy capture ahead of plan and volume growth amid input cost inflation, and the company guided to adjusted diluted EPS of $1.80-$1.90 for its six-month transition period ending December 31, 2026.
Key points
- Amcor's fourth-quarter fiscal 2026 net sales were $6.4 billion, up 26%, with net income of $389 million versus a $39 million loss a year earlier.
- Full-year fiscal 2026 net sales were $23.5 billion, up 57%, largely driven by the April 30, 2025 Berry Global combination; adjusted diluted EPS rose 13% to $4.02.
- Amcor's board declared a quarterly dividend of 65.0 cents per share, payable September 24, 2026 to shareholders of record September 4, 2026.
- Amcor guided to adjusted diluted EPS of $1.80 to $1.90 for the six-month transition period ending December 31, 2026, and leverage of 3.5x-3.6x, as it moves to a December fiscal year-end.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. On August 12, 2026, Amcor plc (the “Company”) issued a press release regarding financial results for the fourth quarter and for the fiscal year ended June 30, 2026. The press release is furnished as Exhibit 99.1 hereto. The Company is not including the information contained on its website as part of, or incorporating it by reference into, this Current Report on Form 8-K. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.